key: cord-0871336-8w8yknth
authors: Ghazanfari, Davoud; Courreges, Maria Cecilia; Belinski, Lydia; Bergmeier, Stephen C.; McCall, Kelly D.; Goetz, Douglas J.
title: Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19
date: 2022-03-16
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2022.03.035
sha: fd17e5f6b4aab3dff10d1be09709cbe1fa0eeff3
doc_id: 871336
cord_uid: 8w8yknth

A key component of severe COVID-19 is a “cytokine storm” i.e., the excessive expression of unneeded cytokines. Previous studies suggest that SARS-CoV-2 proteins can induce macrophages to secrete pro-inflammatory cytokines; a process that may involve Toll-like receptors (TLRs). Glycogen synthase kinase-3 (GSK-3) has been implicated in TLR signal transduction and a selective GSK-3 inhibitor, termed COB-187, dramatically attenuates cytokine expression induced by the TLR ligand lipopolysaccharide (LPS). In the present study, we provide evidence that the SARS-CoV-2 spike protein (S) and the S2 subunit (S2) induce production of CXCL10 (a chemokine elevated in severe COVID-19) by a human macrophage cell line. Further, we report that two clinically relevant GSK-3 inhibitors and COB-187 attenuate S and S2 protein-induced CXCL10 production. Combined, our observations provide impetus for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19.

One of the key features of severe COVID-19 is a "cytokine storm" driven by a dysregulated innate immune response [1] . In general, innate immune cells (e.g., macrophages) sense pathogen associated molecular patterns (PAMPs) via pathogen recognition receptors (PRRs) [e.g., Tolllike receptors (TLRs)] [2] . Ligated PRRs trigger signaling pathways that activate transcription factors leading to the release of cytokines and chemokines (a subset of cytokines) [2] . The SARS-CoV-2 virus has four structural proteins namely, spike (S) which has two main subunits S1 and S2, envelope (E), membrane (M), and nucleocapsid (N) [3] . Multiple studies have probed SARS-CoV-2 protein induction of cytokine expression.

Khan et al. [4] provided evidence that S, but not M, E nor N protein induces cytokine (including chemokine) expression by THP-1 macrophages and human peripheral blood mononuclear cells and that this induction occurs via TLR2 and a NF-kB, MyD88-dependent pathway. Zheng et al. [5] reported that the E protein, but not S, induces the production of proinflammatory cytokines by mouse bone marrow-derived macrophages. Karwaciak et al. [6] found that 3 day incubation of human monocytes and macrophages with the N or S protein induced IL-6 expression. Shirato et al. [7] and Chiok et al. [8] reported that S1 stimulates production of TNF- by THP-1 macrophages and Chiok et al. [8] further reported S1 induction of CXCL10 (a.k.a. IP-10). Zhao et al. [9] found that only the trimeric form of the S protein, but

The THP-1 human monocyte cell line was purchased from American Type Culture Collection (ATTC, Manassas, VA) and cultured according to the manufacturer's protocol. In brief, THP-1 cells were cultured in RPMI-1640 medium (ATCC, Manassas, VA) supplemented with 10% FBS (ATCC, Manassas, VA), 0.05 mM of 2-mercaptoethanol (Millipore, Billerica, MA), and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO), at 37°C and 5.0% CO2. To differentiate THP-1 monocytes to a macrophage phenotype, THP-1 cells were treated with 50 ng/mL of phorbol 12-myristate 13-acetate (PMA) (5244001MG, MilliporeSigma) in growth media for 48

hours. Subsequently, the adherent differentiated cells were washed with growth media and incubated for 24 hours with growth media in the absence of PMA at 37 °C and 5.0% CO2 [18] .

We refer to the differentiated THP-1 cells as THP-1 macrophages throughout the paper.

We obtained the SARS-CoV-2 proteins from ACROBiosystems (Delaware Technology Park).

ACROBiosystems altered the amino acid sequence of the recombinant S and S2 proteins in the middle of our study. Specifically, proline substitutions [F817P, A892P, A899P, A942P, K986P, V987P] were introduced for both proteins and alanine substitutions [R683A and R685A] for the S protein. We refer to the constructs with the substitutions as mutated S and S2; unless otherwise noted, the wild type version of these proteins were used. The mutated and wild type S have different catalog numbers while the mutated and wild type S2 have the same catalog number but different lot numbers. Currently only the mutated version of S2 is listed in the catalog and the wild type can be obtained via special request.

J o u r n a l P r e -p r o o f THP-1 macrophages were treated with growth media containing one of the following proteins: SARS-CoV-2 full length S protein (S) (cat# SPN-C52H8), mutated S (cat# SPN-C52H9), the S1 subunit (S1) (cat# S1NC52H3) , the S2 subunit (S2) (cat# S2N-C52H5, lot# 3621-206GF1-SG and lot#3621-2042F1-X5), mutated S2 (cat# S2N-C52H5, lot# P3840b- which is a potent and selective antagonist of TLR4 [22] , was from Invivogen (cat# tlrl-prslps).

To determine the effect of GSK-3 inhibitors on S and S2 induction of CXCL10, THP-1 macrophages were treated with S or S2 proteins in the presence of 25 or 12.5 µM of GSK-3 inhibitors [9-ING-41 (cat# AOB33534, AOBIOUS INC) [23] , Lithium carbonate (cat# 413261000, Thermo Scientific Chemicals) [24] , LY2090314 (cat# SML1438, MilliporeSigma) [25] , Tideglusib (cat# SML0339, MilliporeSigma) [26] , AZD-1080 (cat# HY-13862, MedChemExpress) [27] , or COB-187 [17] , [18] , and [28] generated by S. Bergmeier at Ohio University], or dexamethasone (cat# 0219004090, MP Biomedicals, Inc) which is currently used J o u r n a l P r e -p r o o f in the treatment of SARS-CoV-2 patients [29] . Negative controls were THP-1 macrophages treated with fresh media in the presence of 1% DMSO (i.e., carrier control for the GSK-3 inhibitors). Subsequent to the treatments described in the above paragraphs, the THP-1 macrophages were incubated for 6 hours under standard cell culture conditions. After the incubation, the supernatants were harvested and the level of CXCL10 in the supernatants determined via ELISA as described below.

The human CXCL10/IP-10 ELISA kit (cat# KAC2361, R&D Systems) was used to quantify the presence of CXCL10 protein in culture supernatants. The assay was performed according to the manufacturer's protocol with the exception that the supernatants were diluted 1:2 rather than 1:10 with Standard Diluent Buffer. A standard curve was generated using CXCL10 provided by the supplier. This curve was used to estimate the level of CXCL10 present in supernatants from the S and S2 treated THP-1 macrophages. To maximize utilization of resources, this analysis was only done for a small set of experiments. (Fig 1A) . In contrast, an irrelevant protein, GFP, did not induce CXCL10 expression while N induced quite limited, albeit statistically significant, CXCL10 expression (Fig. 1B) . S2, but not S1, as well as LPS (positive control) induced significant CXCL10 at the conditions tested (Fig. 1C) .

Endotoxin in the Protein Preparations While the above observations suggest that S and S2 can induce robust CXCL10 expression, commercially available protein preparations can be contaminated with endotoxin which may confound data interpretation [31] . Thus, we assayed for the presence of endotoxin using the indirect LAL assay ( Fig. 2A left panel) , which measures sample-induced coagulation, and the EndoLISA which is a direct measure of endotoxin ( Fig. 2A, right panel) . The LAL results were conflicted regarding the presence of endotoxin in the samples. While both the S and S2 preparations appeared to give a modest signal, the signal was not reduced by polymyxin B (PB) which can neutralize endotoxin present in protein preparations [32] (Fig. 2A left panel) . To the latter point, PB did indeed abolish the LPS signal in both the assays ( Fig. 2A left and right panels). The EndoLISA appeared to detect a low level of endotoxin in the S and S2 protein preparations (~4% and ~7%, respectively, of the nominal 1 EU/ml LPS signal) which were reduced to background levels by PB ( Fig. 2A, right panel) .

CXCL10 expression by THP-1 macrophages (Fig. 2B) . In sharp contrast, treatment of THP-1 macrophages with S or S2 in the presence of PB yielded robust CXCL10 expression (Fig. 2B) . S1, which gave a signal in the LAL assay, did not induce significant CXCL10 expression in the J o u r n a l P r e -p r o o f absence or presence of PB ( Fig. 1C and 2B) . Several reports demonstrate that LPS utilizes TLR4 to induce cytokine expression [33] . LPS-RS is a potent and selective antagonist of TLR4 [22] .

Thus, to further probe the possibility of contaminating endotoxin underlying S and S2 induction of CXCL10 expression, and to begin to gain insight into the mechanism of induction, we treated THP-1 macrophages with S and S2 proteins and 1 EU/mL ultrapure LPS in the presence of 100 ng/mL of LPS-RS. We observed that LPS-RS had no significant effect on S and S2 induction of CXCL10 (Fig. 2C) . In clear contrast, LPS-RS significantly diminished LPS-induced CXCL10 expression (Fig. 2C) . Combined, the data presented in Fig. 2 are consistent with the interpretation that it is the S and S2 proteins, and not contaminating endotoxin, that induces CXCL10 expression.

During the course of this study, the supplier of S and S2 altered the amino acid sequence of the S and S2 recombinant proteins. Specifically, they modified F817P, A892P, A899P, A942P, K986P, V987P on both proteins and R683A and R685A on the S protein. Surprisingly, the modified versions of S and S2 did not induce CXCL10 (Fig. 3) . Data provided by the supplier indicated that both the "wild-type" and proline mutated S protein exist predominantly in the trimeric state while both versions of the S2 proteins are in the monomeric state. This observation would appear to eliminate the possibility of a change in the trimeric/monomeric state of the proteins as the cause of the observed differences in the activity of the "wild-type" versus the mutated proteins.

We next explored the effect of GSK-3 inhibitors on S and S2 induction of CXCL10 using COB-187 and more clinically advanced GSK-3 inhibitors, specifically: lithium (a weak GSK-3 inhibitor used clinically [24] ); Tideglusib [26] and 9-ING-41 [23] (currently in clinical trials);

and AZD-1080 [27] and LY2090314 [25] (previously in clinical trials). We observed that 25 and 12.5 µM of COB-187, LY2090314, and AZD-1080, significantly reduced S-induced CXCL10 expression ( Fig 4A) . Lithium, Tideglusib, and 9-ING-41 appeared to have little, if any effect.

Dexamethasone, currently used to treat severe COVID-19 in the later stages of the disease [29] , did not significantly inhibit S-induction of CXCL10 (Fig. 4A) . Similar results were observed with S2-induction of CXCL10 (Fig. 4B ) with the exception that 12.5 µM LY2090314 had little, if any, effect. While we did not observe inhibition by Lithium, and Tideglusib, we only tested a limited number of conditions. It is entirely possible that inhibition could be observed under a different set of conditions [e.g., lower concentration of S or S2 protein (the level of CXCL10 induced by 25 nM of the spike proteins was ~500 -1000 pg/ml), preincubation with the inhibitor prior to treatment with spike protein, higher concentration of inhibitor]. This caveat might be particularly important for lithium since it is known to be a weak GSK-3 inhibitor [34] .

In summary, in line with other recent studies [4] [10] we have found evidence that SARS-CoV-2 S and S2 proteins induce cytokine expression, in particular the chemokine CXCL10.

Under the conditions tested, we found that two clinically relevant GSK-3 inhibitors and COB-J o u r n a l P r e -p r o o f 187, a novel GSK-3 inhibitor, attenuate S and S2 induction of CXCL10. These results provide impetus for investigating GSK-3 inhibitors as potential therapeutics for COVID-19.

Ohio University owns patents related to COB-187. SCB, KDM, and DJG are inventors on the patents. with wild type (blue bars) or mutant (red bars) S or S2 proteins, or media alone, in the absence or presence of 30 µg/mL PB for 6 hours and the level of CXCL10 in the supernatants subsequently determined. Error bars: SEM (n=2). *p<0.05 as determined by a two-tailed t-test comparing wild type to mutant for each condition. Mutant S and S2 are described in the methods section. 

Cytokine storm

Signaling in innate immunity and inflammation

Structural proteins in severe acute respiratory syndrome coronavirus-2

spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway

TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines

Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophagespotential implications for cytokine storm syndrome

SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages

Proinflammatory responses in SARS-CoV-2 infected and soluble spike glycoprotein S1 subunit activated human macrophages, bioRxiv

CoV-2 spike protein interacts with and activates TLR4

SARS-CoV-2/ACE2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages

Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications

The renaissance of GSK3

Molecular cloning and expression of glycogen synthase kinase-3/factor A

Glycogen synthase kinase-3 from rabbit skeletal muscle separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase

Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3

Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions

Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor

Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3

Inflammatory role of TLR-MyD88 signaling in multiple sclerosis

IRF3 mediates a TLR3/TLR4-specific antiviral gene program

Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one!

Lipopolysaccharide from rhodobacter sphaeroides attenuates microglia-mediated inflammation and phagocytosis and directs regulatory T Cell response

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

A Low-therapeutic dose J o u r n a l P r e -p r o o f of lithium inhibits GSK3 and enhances myoblast fusion in C2C12 cells

A Study of LY2090314 and chemotherapy in participants with metastatic pancreatic cancer

A phase II trial of tideglusib in Alzheimer's disease

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism

Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence

EndoLISA®: a novel and reliable method for endotoxin detection

Heat shock proteins and immune system

Polymyxin B as inhibitor of LPS contamination of schistosoma mansoni recombinant proteins in human cytokine analysis

Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM

Lithium-mediated phosphorylation of glycogen synthase kinase-3β involves PI3 kinasedependent activation of protein kinase C-α

Health [R15GM110602; to KDM, SCB and DJG].